Cargando…

Interleukin-6 as a potential biomarker of COVID-19 progression

Detalles Bibliográficos
Autores principales:	Ulhaq, Zulvikar Syambani, Soraya, Gita Vita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Masson SAS. 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129451/ https://www.ncbi.nlm.nih.gov/pubmed/32259560 http://dx.doi.org/10.1016/j.medmal.2020.04.002

Ejemplares similares

The prevalence of ophthalmic manifestations in COVID-19 and the diagnostic value of ocular tissue/fluid
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2020)

Breakthrough COVID-19 case after full-dose administration of CoronaVac vaccine
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2021)

Interleukin-6 levels in children developing SARS-CoV-2 infection
por: Soraya, Gita Vita, et al.
Publicado: (2020)

Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2020)

Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2020)

Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis
por: Soraya, Gita Vita, et al.
Publicado: (2020)

Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis
por: Soraya, Gita Vita, et al.
Publicado: (2020)

An urgent call to identify the probable cause of severe acute hepatitis outbreak in children
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2022)

The role of IL-6-174 G/C polymorphism and intraocular IL-6 levels in the pathogenesis of ocular diseases: a systematic review and meta-analysis
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2020)

Nanotheranostics: A powerful next-generation solution to tackle hepatocellular carcinoma
por: Ladju, Rusdina Bte, et al.
Publicado: (2022)

Association between GPER gene polymorphisms and GPER expression levels with cancer predisposition and progression
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2021)

A Roadmap for Future Parkinson's Pharmacogenomics in Asia
por: Akbar, Muhammad, et al.
Publicado: (2022)

The prevalence of anxiety symptoms and disorders among ophthalmic disease patients
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2022)

The Association Between Genetic Polymorphisms in Estrogen Receptor Genes and the Risk of Ocular Disease: A Meta-Analysis
por: Ulhaq, Zulvikar Syambani
Publicado: (2020)

Brain aromatase modulates cardiac functions in embryonic zebrafish
por: Ulhaq, Zulvikar Syambani
Publicado: (2019)

Investigating the association of physical and psychological problems with the levels of interleukin-1 and -6 in COVID-19 patients
por: Bahadori-Birgani, Galia, et al.
Publicado: (2023)

Delayed versus immediate intervention of ruptured brain arteriovenous malformations: A case report
por: Bintang, Andi Kurnia, et al.
Publicado: (2023)

Brain Aromatase Modulates Serotonergic Neuron by Regulating Serotonin Levels in Zebrafish Embryos and Larvae
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2018)

A Brief Analysis of Proteomic Profile Changes during Zebrafish Regeneration
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2021)

The effect of digital acupressure on chemotherapy-induced nausea in Indonesian patients with stages III-IV breast cancer
por: Wicaksono, Beni, et al.
Publicado: (2023)

Data on attitudes, religious perspectives, and practices towards COVID-19 among Indonesian residents: a quick online cross-sectional survey
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2020)

Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19
por: Vityala, Yethindra, et al.
Publicado: (2021)

Potential Biomarkers for Defining the Severity, Progression, and Survival from COVID-19
por: Okechukwu, Chidiebere Emmanuel
Publicado: (2021)

Interleukin-6 and severity of COVID-19 patients in Hefei, China
por: Zhao, Z., et al.
Publicado: (2020)

Interleukin-17: A potential therapeutic target in COVID-19
por: Mendoza, Vicky M. Montaño
Publicado: (2020)

Interleukin 6: A biomarker for COVID-19 progression
por: Sebbar, El-houcine, et al.
Publicado: (2023)

Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19
por: Gade, Akhil R., et al.
Publicado: (2020)

Interleukin-6 and statin therapy: potential role in the management of COPD
por: Young, Robert P, et al.
Publicado: (2013)

Interleukin-6 blockade with tocilizumab in COVID-19: Does it live up to its hype?
por: Kow, C.S., et al.
Publicado: (2021)

Kinetics of serum hepcidin and interleukin-6 levels following COVID-19 infection in hemodialysis patients
por: Touzot, Maxime, et al.
Publicado: (2021)

The cytokine interleukin-26 as a biomarker in pediatric asthma
por: Konradsen, Jon R., et al.
Publicado: (2016)

Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?’
por: Kow, Chia Siang, et al.
Publicado: (2023)

Interim interleukin 6 levels correlate with progression-free survival in patients with classic Hodgkin's disease: a pilot study
por: Villanova, Pamela, et al.
Publicado: (2020)

Right atrial myxoma: a potential accelerator of pulmonary hypertension in the course of systemic sclerosis. The role of interleukin-6
por: Peregud-Pogorzelska, Małgorzata, et al.
Publicado: (2019)

Ketamine, Interleukin-6, and Vasoplegia: Is Prevention the Best Medicine?
por: Ortoleva, Jamel P.
Publicado: (2023)

IL-6 may be a good biomarker for earlier detection of COVID-19 progression
por: Wang, Changsong, et al.
Publicado: (2020)

Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19
por: Dimosiari, Athina, et al.
Publicado: (2023)

Consecutive Monitoring of Interleukin-6 Is Needed for COVID-19 Patients
por: Chen, Xiaohua, et al.
Publicado: (2021)

Increased serum interleukin-6 levels in patients with hidradenitis suppurativa
por: Xu, Haoxiang, et al.
Publicado: (2017)

Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series
por: Nakamura, Hideta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gc705une2v8r4d0dpkljhvrafb